Adam Fine is Co-Founder, General Partner, and CEO of Windham Capital Partners. Adam is currently a Board Director at RxWare, Neuspera, Andros, and Valera, and Board Observer to Chromacode, and Upward Health. Prior to Windham, Adam was VP & GM at I-many, Inc., a healthcare enterprise software company. Before joining I-many, Adam was a Business Development Analyst at Cordis & Biosense, both Johnson & Johnson companies focused on interventional vascular and electrophysiology devices and worked closely with JJDC, Johnson & Johnson's venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.

‍